Krishnaraju Venkata Subramanian, Singh Harmandeep, Kumar Rajender, Sharma Sarika, Mittal Bhagwant Rai, Bhattacharya Anish
Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Br J Radiol. 2021 Jun 1;94(1122):20201204. doi: 10.1259/bjr.20201204. Epub 2021 May 12.
Localizing the sites of infection in the body is possible in nuclear medicine using a variety of radiopharmaceuticals that target different components of the infective and inflammatory cascade. Gamma(γ)-emitting agents such as [67Ga]gallium citrate were among the first tracers used, followed by development of positron-emitting tracers like 2-deoxy-2-[18F]fluoro-D-glucose (F-FDG). Though these tracers are quite sensitive, they have limited specificity for infection due to their concentration in sites of non-infective inflammation. White blood cells (WBC) labelled with γ or positron emitters have higher accuracy for differentiating the infective processes from the non-infective conditions that may show positivity with tracers such as F-FDG. We present a pictorial review of potential clinical applications of PET/CT using F-FDG labelled WBC.
在核医学中,利用多种针对感染和炎症级联反应不同成分的放射性药物,确定体内感染部位是可行的。发射伽马(γ)射线的制剂,如枸橼酸[67Ga]镓,是最早使用的示踪剂之一,随后开发出了发射正电子的示踪剂,如2-脱氧-2-[18F]氟-D-葡萄糖(F-FDG)。尽管这些示踪剂相当敏感,但由于它们在非感染性炎症部位的聚集,对感染的特异性有限。用γ或正电子发射体标记的白细胞(WBC)在区分感染过程与可能对F-FDG等示踪剂呈阳性反应的非感染性情况方面具有更高的准确性。我们展示了使用F-FDG标记白细胞的PET/CT潜在临床应用的图文综述。